ISPOR Europe 2024 Home
Toggle navigation
About
News Center
Program
Program
Student Program
Learning Formats
Plenary Sessions
Posters
Program Committee
Digital Conference Pass
Exhibits & Sponsorship
Sponsor List
Media Partners
Exhibitor Directory
Award Winners
Photo Gallery
ISPOR
Europe 2024
17 - 20 November
Home
Events
Past Conferences
ISPOR Europe 2024
Program
Plenary Sessions
Session
Budget Impact and Cost-Utility Analysis of Naxitamab Plus GM-CSF for the Treatment of Refractory/Relapsed HR-NB in the Brazilian Private Healthcare Population
Dec 3, 2024, 15:13 PM
1
2
(current)
3
4
5
6
7
8
9
10
»